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35-fold  in  patients  with  stage  5  chronic  kidney  disease 
(CKD) (1), and CVD mortality is not reduced upon initia-
tion of dialysis therapy. Although CVD mortality has been 
declining, the rate of infectious hospitalizations and deaths 
has been increasing (4). In observational studies, higher 
total cholesterol and LDL cholesterol (LDL-C) are associ-
ated with better survival in chronic hemodialysis (HD) and 
peritoneal dialysis patients (5–9). Although treatment of 






Abstract Cardiovascular (CV) events are increased 36-fold 
in patients with end-stage renal disease. However, random-
ized controlled trials to lower LDL cholesterol (LDL-C) and 
serum total cholesterol (TC) have not shown significant mor-
tality improvements. An inverse association of TC and LDL-C 
with all-cause and CV mortality has been observed in pa-
tients on chronic dialysis. Lipoproteins also may protect 
against infectious diseases. We used data from 37,250 pa-
tients in the international Monitoring Dialysis Outcomes 
(MONDO) database to evaluate the association between lip-
ids and infection-related or CV mortality. The study began 
on the first day of lipid measurement and continued for up 
to 4 years. We applied Cox proportional models with time-
varying covariates to study associations of LDL-C, HDL cho-
lesterol (HDL-C), and triglycerides (TGs) with all-cause, CV, 
infectious, and other causes of death. Overall, 6,147 patients 
died (19.2% from CV, 13.2% from infection, and 67.6% 
from other causes). After multivariable adjustment, higher 
LDL-C, HDL-C, and TGs were independently associated 
with lower all-cause death risk. Neither LDL-C nor TGs were 
associated with CV death, and HDL-C was associated with 
lower CV risk. Higher LDL-C and HDL-C were associated 
with a lower risk of death from infection or other non-CV 
causes.  LDL-C was associated with reduced all-cause and 
infectious, but not CV mortality, which resulted in the in-
verse association with all-cause mortality. —Kaysen, G. A., X. 
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relationship between LDL-C and other outcomes may pro-
vide insight into potential mechanisms of protection.
The second leading cause of death among HD patients is 
infection  (4).  Epidemiologically,  lipoprotein  levels  have 




LPS binding protein (LBP) that participates in this transfer 






nal function (12) and likely plays a key role in host defense 
against both bacterial and some viral pathogens (13). In-
terventional studies in animal models strongly suggest that 
lipoproteins may potentially play an important role in the 
innate immune response (20–22) and protect against sep-
sis  in experimental  animal models  (19). Additionally,  in-
fection per se may alter the structure and function of 
lipoproteins (22, 23). Thus, it is plausible that the observed 
association of high total cholesterol and LDL-C levels with 
survival  (5–7)  and  the  lack  of  an  effect  of  lipid-lowering 
therapies  on  all-cause mortality  in  interventional  studies 
(11) is based at least in part upon a protective effect of lipo-




tious event as opposed to their levels during infection, as 
well  as  to  control  for  variables  associated with  inflamma-
tion to try to separate cause from effect. We conducted a 
retrospective cohort study to analysis the outcomes in an 




infectious diseases, and death attributed to cardiovascular 
(CV), and in order to establish whether any protective ef-


























before  the data were  integrated  into a master database. All  the 
research conducted by the MONDO Initiative complied with na-
tional and international ethical, compliance, and legal standards. 
The  study  was  approved  by  the  Western  Institutional  Review 
Board (ES-16-005).










ered from renal failure) occurred (Fig. 1B).
Exposures and outcomes




after initial start of renal replacement therapy) also measured 
routinely in majority of the study cohort, each of the parameters 
of  interest was  treated  as  a  time-dependent parameter while 
performing the analyses. The primary outcomes of interest were 








ered died due  to  infection-related or CV-related  if  the primary 
International Classification of Diseases (ICD), 9th revision, Clini-
cal Modification (for RRI’s patients) or  ICD, 10th  revision (for 
Europe and West Asia’s patients) diagnosis  code was  related  to 
infection-related or CV-related hospitalizations. The correspond-
ing  documented  free-text  descriptions  were  applied  to  further 
validate the cause-specific mortalities.
Statistical analyses
Continuous  variables were  reported as means  (± SD) or me-
dian (interquartile range) depending on the distribution of the 
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models. Up to 48 time-varying values of each lipoprotein per par-
ticipant using lipoprotein values measured at different time 
points were included in each analysis. For patients with more than 
one lipid measurement during the baseline period, the previous 
value was replaced by the upcoming value while conducting the 
analyses. To account for changes in serum lipid levels over time 
and assess  the associations between  lipid  levels and each of  the 
cause-specific deaths, the following six models with incremental 
levels of adjustments were conducted: 1) model 1: each serum li-
poprotein (noted as continuous value) with age, dialysis vintage, 
gender, vascular access, and BMI, as well as the geographical 





erable  model,  which  contained  nutritional  and  inflammation 






Clinical and laboratory analyses
Clinical and laboratory data were directly imported electroni-
cally in all the European, West Asian, and all North America-RRI 
clinics.  All  the  lipoproteins  were  measured  routinely  from 
monthly to half-yearly in Europe and West Asia clinics, measured 
annually in FMC-RRI clinics. Serum albumin was measured by the 


















No. of patients 37,250 6,147 1,183 812 4,152 31,103
Age (years), Median  
(Q1, Q3)
64 (52, 74) 72 (63, 79) 71 (62, 78) 72 (63, 79) 73 (63, 79) 62 (51, 73)
BMI 25.71 ± 6.62 24.27 ± 5.48 24.74 ± 5.06 24.59 ± 5.54 24.06 ± 5.58 26.72 ± 5.57
Diabetics (%) 15.57 18.50 17.95 21.43 18.08 15.00
Gender: male (%) 58.60 59.77 62.55 57.64 59.39 58.37
Catheter (%) 44.68 47.37 50.04 47.04 46.68 44.14
Vintage (years),  
Median (Q1, Q3)
3.04 (0.13, 4.15) 2.63 (0.11, 3.78) 2.73 (0.11, 4.00) 2.51 (0.10, 3.41) 2.64 (0.11, 3.74) 3.12 (0.13, 4.24)
Serum albumin (g/dl) 3.85 ± 0.42 3.68 ± 0.49 3.75 ± 0.45 3.62 ± 0.52 3.67 ± 0.49 3.89 ± 0.41
Serum creatinine 
([mg/dl)
7.74 ± 2.35 6.77 ± 2.09 6.96 ± 2.07 6.74 ± 2.08 6.72 ± 2.09 7.94 ± 0.36
CRP (mg/dl),  
Median (Q1, Q3)
8.73 (1.16, 10.09) 12.64 (1.83, 16.00) 11.29 (1.53, 15.07) 14.76 (2.66, 19.34) 12.61 (1.82, 15.72) 7.96 (1.08, 1.24)
NLR 3.22 ± 2.47 3.75 ± 3.00 3.52 ± 2.05 4.00 ± 3.40 3.77 ± 3.11 3.12 ± 2.34
LDL-C (mmol/l)
 All regions 2.45 ± 0.87 2.39 ± 0.88 2.46 ± 0.92 2.30 ± 0.91 2.39 ± 0.87 2.47 ± 0.87
  Eastern Europe  
(n = 6,246)
2.64 ± 1.02 2.54 ± 0.97 2.57 ± 1.03 2.51 ± 1.00 2.53 ± 0.95 2.66 ± 1.03
  Southern Europe  
(n = 18,358)
2.27 ± 0.78 2.21 ± 0.81 2.20 ± 0.83 2.18 ± 0.83 2.22 ± 0.81 2.29 ± 0.77
  Western Europe  
(n = 1,058)
2.31 ± 0.93 2.31 ± 0.93 2.20 ± 0.83 2.05 ± 1.63 2.35 ± 0.92 2.31 ± 0.93
  West Asia (n = 10,699) 2.71 ± 0.83 2.70 ± 0.87 2.84 ± 0.85 2.65 ± 1.03 2.67 ± 0.85 2.71 ± 0.83
 United States (n = 888) 2.03 ± 0.82 2.08 ± 0.81 1.96 ± 0.87 2.15 ± 0.71 2.07 ± 0.82 2.02 ± 0.82
HDL-C (mmol/l)
 All regions 1.05 ± 0.34 1.03 ± 0.34 1.01 ± 0.32 1.07 ± 0.34 1.03 ± 0.34 1.06 ± 0.34
  Eastern Europe  
(n = 6,246)
1.06 ± 0.36 1.00 ± 0.39 1.06 ± 0.39 1.04 ± 0.38 0.98 ± 0.38 1.07 ± 0.36
  Southern Europe  
(n = 18,358)
1.14 ± 0.34 1.11 ± 0.33 1.09 ± 0.34 1.14 ± 0.33 1.11 ± 0.33 1.15 ± 0.34
  Western Europe  
(n = 1,058)
1.90 ± 0.41 1.12 ± 0.35 1.14 ± 0.41 1.32 ± 0.19 1.11 ± 0.34 1.20 ± 0.42
  West Asia (n = 10,699) 0.89 ± 0.26 0.88 ± 0.27 0.87 ± 0.24 0.84 ± 0.25 0.89 ± 0.27 0.90 ± 0.25
 United States (n = 888) 1.09 ± 0.37 1.10 ± 0.38 1.00 ± 0.31 1.06 ± 0.30 1.11 ± 0.40 1.09 ± 0.36
TG (mmol/l)
 All regions 1.86 ± 1.02 1.72 ± 0.95 1.80 ± 1.01 1.71 ± 0.95 1.69 ± 0.93 1.89 ± 1.02
  Eastern Europe  
(n = 6,246)
1.92 ± 1.13 1.87 ± 1.10 1.81 ± 1.13 1.89 ± 0.94 1.89 ± 1.11 1.93 ± 1.14
  Southern Europe  
(n = 18,358)
1.74 ± 0.88 1.57 ± 0.78 1.63 ± 0.82 1.59 ± 0.78 1.55 ± 0.77 1.77 ± 0.90
  Western Europe  
(n = 1,058)
1.63 ± 0.90 1.42 ± 0.68 1.50 ± 0.78 1.17 ± 0.71 1.41 ± 0.66 1.65 ± 0.91
  West Asia (n = 10,699) 2.07 ± 1.13 1.93 ± 1.09 2.06 ± 1.18 1.98 ± 1.28 1.88 ± 1.04 2.10 ± 1.14




1522 Journal of Lipid Research Volume 59, 2018
All the clinical and laboratory parameters that were measured by 









(16.77%)  from  Eastern  Europe,  18,358  (49.28%)  from 
Southern  Europe;  1,058  (2.84%)  from Western  Europe; 
10,699  (28.72%)  from West Asia;  and 888  (2.38%)  from 
United  States-RRI.  Patient  characteristics  stratified  by 
cause-specific  death  are  presented  in Table 1.  The  flow 




due to infections, 4,024 died due to any other causes that 
are not CV and not infections, and 57 (0.9%) had missing 




and TG  (HR:  0.77,  95% CI:  0.75–0.79)  levels were posi-
tively associated with survival in HD patients (Table 2). By 




ment  for  demographics  and  diabetic  status,  as  well  as 
following adjustment  for nutritional marker, noted as  se-
































HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
LDL (mmol/l) 0.87 (0.84–0.89) <0.0001 0.97 (0.92–1.03) 0.32 0.78 (0.72–0.84) <0.0001 0.84 (0.82–0.87) <0.0001
HDL (mmol/l) 0.68 (0.64–0.74) <0.0001 0.61 (0.52–0.73) <0.0001 0.89 (0.74–1.07) 0.22 0.70 (0.65–0.76) <0.0001
TG (mmol/l) 0.79 (0.77–0.82) <0.0001 0.90 (0.85–0.95) 0.0001 0.77 (0.71–0.83) <0.0001 0.77 (0.74–0.79) <0.0001
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significant after adjustment  for demographics  (HR: 0.75; 
95% CI:  0.68–0.83; Fig. 4, model 1), demographics plus 
diabetic status (HR: 0.77; 95% CI: 0.70–0.86; Fig. 4, model 
2), demographics, plus diabetes, creatinine (HR; 0.78; 95% 
CI: 0.70–0.86; Fig. 4, model 3),  and  in  the  fully adjusted 
model (HR: 0.83; 95% CI: 0.75–0.91; Fig. 4, model 6), al-
though there was some attenuation in the protective effect 
after  adjusting  for  creatinine  and  albumin.  HDL-C  was 
protective against infectious mortality in univariate and 
multivariate analyses (Table 2 and Fig. 4) independent of 
both nutritional and inflammatory biomarkers. TGs were 




but not  following adjustment  for  serum albumin (Fig.  4, 
models 4 and 6).








Mortality  is  inversely  associated  with  total  cholesterol 
and LDL-C cholesterol in the dialysis population (7, 32) in 













els and mortality in the general population is primarily a 
consequence of vascular disease (34), our observations that 
LDL-C  levels have no  association with CV outcomes par-
tially  explain  the  difference  between  the dialysis  popula-
tion and general population. Part of the residual protective 
effect of lipoproteins, accounting for their association with 
reduced mortality, appears to be a consequent part of re-





The finding of reduced infectious mortality may be 
linked  to  known  protective  effects  both  of  HDL-C  and  
of other  lipoprotein classes.  Infection has been shown to 
affect the structure of lipoproteins (22, 23) and lipoprotein 





or  calcium  and  phosphorous  metabolism  (39,  40)  that 
play a more limited role in the general population are re-
sponsible for the large increase in CVD outcomes (1) and 
dominate CVD outcomes in dialysis patients, obscuring li-






patients at any level of cholesterol. We found no effect of 





LDL-C reduces infectious risk in dialysis patients 1525
both in this population as well as in a smaller prospective 
study in which LDL-C was measured directly (41), although 
infectious hospitalizations rather than infectious mortality 
were  the  primary  outcome  in  that  study.  The  question 
raised  then now  is not why LDL-C  levels do not  increase 
mortality risk, but what is the mechanism whereby LDL-C is 







founded by severity of inflammation, because greater inflam-
mation is expected to reduce lipid levels more (24, 26, 44, 
45). Our observations here are strengthened by the predic-
tive effect of measurements carried out at a time distant from 
the outcomes, as much as 4 years prior to any event noted. 
Furthermore, in longitudinal analysis of the relationship be-




The observation that infectious mortality is inversely 
associated with both LDL-C and HDL-C levels, even after 
adjusting for nutritional and inflammatory markers, is con-
sistent  with  prior  observations  by  us  (41)  and  consistent 
with reported protective effect of LDL-C and other lipopro-
teins from infection or bacterial toxins (19, 20) and protec-
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in dialysis patients (54, 55) would be expected both to in-
crease CV risk from inflammation and change the overall 
effect of lipoproteins, specifically of LDL-C, to favor protec-
tion, as observed here.
HDL-C contains LBP (17), an acute phase protein that is 
in part carried by HDL-C and plays a role in neutralizing 
the  biological  effect  of  LPS  (56),  in  part  by  transferring 
LPS  from HDL-C  to  lipoproteins  targeted by  the hepatic 




may be more difficult to estimate from these data because 




is observed in the general population for total cholesterol 
(34). Unlike the statistically significant reduction in infec-
tious death, there is no obvious mechanism to explain the 
protective  effect  of  LDL-C  and  HDL-C  against  residual 
causes of death, and one weakness of this study is that we 
did not further analyze the distribution of deaths not asso-
ciated with CV or infectious hospitalizations. Many of these 





be a protective effect of total cholesterol and cancer 
outcomes  in  some  forms of  cancer  (60),  although  there 
may  be  confounding  effects  of  nutritional  intake  as  well 
(34); however, the relationship between cancer death, and 









associated  with  reduced  levels  of  nutritional  biomarkers 
and decreased lipid levels (47). A variety of nutritional 







lower  than  reported  by  the U.S.  Renal Data  System  (4); 
however, we focused our CV classification to represent arte-
rial injury rather than all CV events that may be due to vol-
ume overload or electrolyte abnormalities. Although the 
majority of our study cohort is from Europe, the event rate 
is similar to those reported in a European population fo-
cusing on the same outcomes (59).
One of the strengths of current study is that the sample 
size is relatively large, and the sample was diverse according 
to geographical  regions. This  allowed us  to  study  regions 
that routinely perform lipid panels as well as CRP measure-
ment without indication reducing a selection bias  in sam-
pling.  Most  of  the  study  cohort  is  from  Europe,  which 
contains more than 95% white patients, which may limit the 
applicability of these finding to other racial groups. Al-
though the current study is a retrospective observational 
study, we have very limited documentation of medication to 
include in this analysis in the current study. Another limita-
tion  of  the  current  study  is  that  we  do  not  have  enough 
documentation of comorbid conditions in the current sub-
set study cohort. Furthermore, a number of additional nu-
tritional related biomarkers—Subjective Global Assessment, 
muscle mass, skin fold thickness—are unavailable. Thus, 
residual confounding factors still cannot be eliminated.
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